newswire, breaking biotechnology and pharma news

Monday, May 2, 2016

Q BioMed Inc (OTCQB: $QBIO) News: Mannin Research to Participate at ARVO 2016 Meeting

Q BioMed Inc (OTCQB: $QBIO) News: Mannin Research to Participate at ARVO 2016 Meeting

NEW YORK - May 2, 2016 ( Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company announces that its technology partner Mannin Research Inc. will be attending the Association for Research in Vision and Ophthalmology (ARVO), which takes place from May 1-5, 2016 in Seattle Washington. Mannin Research executives will be meeting with its vendors and research partners. The meeting provides organizations the opportunity to further explore business development goals and other collaborative opportunities for the MAN-01 program for treatment of glaucoma.

The ARVO annual meeting is the largest gathering of eye and vision researchers in the world. The annual meeting runs from May 1st to 5th at the Washing State Convention Center in Seattle, Washington, attracting over 11,000 attendees from more than 75 countries.

Mannin's CEO, Dr. George N. Nikopoulos stated: "We are very pleased to be attending the meeting. We are looking forward to engaging in meaningful research discussions and exploring possible collaboration opportunities with other innovative groups in attendance."

In October 2015 Q BioMed Inc entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics. Mannin's primary focus is developing a first-in-class therapeutic eye-drop for glaucoma in adults and children, using a research platform designed to help develop new drugs for that indication and cystic kidney disease, among other diseases. Lead drug candidate MAN-01 is designed to treat abnormal vessels within the eye-thus treating glaucoma at its root causes.

We invite our shareholders and interested parties to subscribe to our email list and stay informed on our website at and follow us on the social media feeds we use.

About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Denis Corin
Q BioMed Inc.
1 888 357 2435 

Visit this Company:

More info on QBIO at

Sign up for the free investor news and stock alerts:

This news is published on the Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:
Disclosure: QBIO has retained for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

No comments:

Post a Comment